Acorda Therapeutics Inc reports results for the quarter ended in March - Earnings Summary

Acorda Therapeutics

06/05/2021 23:44

* Acorda Therapeutics Inc  ACOR.OQ  reported a quarterly
adjusted loss of $2.46​​ per share for the quarter ended
in March. The lone analyst forecast for the quarter was for a
loss of $2.54 per share.
* Revenue rose 2.7% to $28.86 million from a year ago​; 
analysts expected $22.15 million.
* Acorda Therapeutics Inc's reported EPS for the quarter was a
loss of $3.53​.
* The mean earnings estimate of analysts had fallen by
about 48.5% in the last three months.​ 
* In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
* Acorda Therapeutics Inc shares had risen by 1.0% this
quarter and gained 18.8% so far this year.
* The company reported a quarterly loss of $33.45 million.
* Wall Street's median 12-month price target for Acorda
Therapeutics Inc is $17.50 
* The current average analyst rating on the shares is "hold" and
the breakdown of recommendations is no "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 
This summary was machine generated May 6 at 10:44 p.m. GMT. ​All
figures in US Dollars.​